Home > Addiction to transmucosal fentanyl: is it a cause for concern in cancer pain management?

Cahill, Kathleen and Shehab, Ruqaya Mohsen and Lowney, Aoife and McQuillan, Regina (2015) Addiction to transmucosal fentanyl: is it a cause for concern in cancer pain management? Palliative medicine , 29 , (9) , pp. 861-862.


Transmucosal fentanyl (TMF) is a µ-receptor agonist used in the management of pain in patients with cancer.1 Current licensing restrictions allow for prescribing of TMF only in patients with cancer who are opioid tolerant and taking the equivalent of 60 mg oral morphine daily. In the United States, prescribers and dispensers of TMF must be specifically certified and enrolled to do so. It has previously been reported that off-label use of TMF can be as high as 90%.....

Item Type:Article
Date:30 June 2015
Page Range:pp. 861-862
Publisher:Sage
Volume:29
Number:9
EndNote:View
Related URLs:
Subjects:B Substances > Opioids (opiates)
B Substances > Opioids (opiates) > Opioid product > Fentanyl
E Concepts in biomedical areas > Substance by legal status > Prescription drug (medicine / medication)
G Health and disease > Pathologic process > Cancer
VA Geographic area > Europe > Ireland

Click here to request a copy of this literature (must be logged in)

Repository Staff Only: item control page